Merries Baby Diaper Business: Struggles to Continue Despite Company Remarks a Quick Turnaround
Kao is a well-known Japanese conglomerate involved in various business activities ranging from FMCG products to chemicals. The company operates in...
562 Views
Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
592 Views
Climate Action - School Strikes Hit a Spot, Carbon Emitters Face Heat. Investors Take Note
On Friday, March 15th, an estimated 1.6 million students in over 120 countries (source: Time magazine) walked out of classrooms and took to streets...
688 Views
Biosimilar Battlefield: The Remsima/Inflectra Warning
2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...
696 Views
Amarin--2019's Biggest Buyout Target for Big Pharma
Amarin (AMRN US), a US-listed biotech firm, presented the full results of its "Reduce-It" (RI) clinical trial at a conference for the American...
4.7k Views